Elizabeth Walker Wadsworth, MD, MSCR, Joins Advanced ENT & Allergy, Bringing Expert ENT and Inspire® Sleep Apnea Care to Atlanta
Dr. Wadsworth returning to Atlanta to treat the community she grew up in.
Share
Dr. Wadsworth earned her medical degree from Emory University School of Medicine and completed her residency in Otolaryngology–Head and Neck Surgery at the Medical University of South Carolina (MUSC), a top-ten residency program nationally. She is board-eligible in otolaryngology and is committed to delivering individualized, evidence-based care that improves breathing, hearing, and sleep health.
'As someone who grew up in Buckhead, it's a privilege to return home to care for patients in the city that shaped me,' said Dr. Wadsworth. 'Whether I'm helping a patient breathe easier, hear better, or finally sleep soundly, I strive to combine the best available treatments with genuine compassion and clear communication.'
During her residency, Dr. Wadsworth gained extensive experience in advanced sinus surgery, ENT allergy management, pediatric and adult hearing loss, and the surgical implantation of the Inspire® upper airway stimulation system — an effective alternative for patients with obstructive sleep apnea who cannot tolerate CPAP therapy.
Dr. Wadsworth is now accepting new patients at Advanced ENT & Allergy, located at 960 Johnson Ferry Rd NE, Suite 200, Atlanta, GA 30342.
https://AdvancedENTpc.com
About Advanced ENT & Allergy
Advanced ENT & Allergy is a leading provider of comprehensive ear, nose, and throat care in the Atlanta area. Our board-certified providers emphasize advanced treatment options, patient education, and individualized service in a welcoming, service-oriented environment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI). Managing blood pressure instability is a major unmet need after SCI, with a significant impact on cardiovascular health and quality of life. Approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe are expected to participate. EINDHOVEN, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the ARC-IM System. With this approval, the Company can initiate the Empower BP pivotal study to assess the safety and efficacy of its implantable spinal stimulation system to address blood pressure instability after SCI. Empower BP is the Company's second global pivotal study, and the first to evaluate the implantable ARC-IM System. The randomized, double-blinded, sham-controlled study is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe, with first patient enrollment anticipated before the end of the year. The study will target participants with injuries at spinal cord levels C2-T6, injury severities of AIS A-D, and blood pressure instability characterized by chronic orthostatic hypotension (OH) and episodes of autonomic dysreflexia (AD). 'This is an important milestone for ONWARD and the SCI community,' said Dave Marver, CEO of ONWARD. 'Our ARC-IM System is designed to address several unmet needs, including blood pressure instability which is a major recovery target after spinal cord injury. With this IDE approval, we continue to advance our innovation pipeline and inspire realistic hope in restoring autonomic functions and independence after SCI and other movement disabilities.' Over 50% of people with SCI experience blood pressure instability, affecting nearly 350,000 people in the US and Europe.1 Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and quality of life. The most frequent symptoms include dizziness, lightheadedness, blurred vision and fatigue.2 'Blood pressure instability, especially chronic low blood pressure, is one of the most hidden and unrecognized functional complications of spinal cord injury,' explains Dr. James Guest, neurosurgeon and Professor of Neurological Surgery at the University of Miami. 'It leaves people feeling unwell and can significantly impact their overall quality of life. Blood pressure instability also increases the risk of cardiovascular disease, making addressing this unmet need critical for improving the long-term outcomes of SCI.' The ONWARD ARC-IM System is an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation. It is the first neuroprosthetic system designed to manage blood pressure instability in people with SCI. It comprises the implanted ONWARD Neurostimulator (IPG) and the ARC-IM Thoracic Lead. The ARC-IM Thoracic Lead is optimized for surgical placement in a specific region of the thoracic spinal cord, called the 'Hemodynamic Hotspot'. The location was first discovered by the Company's research partners at the Swiss Federal Institute of Technology Lausanne (EPFL), Centre Hospitalier Universitaire Vaudois (CHUV), and the University of Calgary in a study published in Nature in January 2021.3 In December 2022, the Company announced positive top-line interim clinical results from its feasibility studies showing improved blood pressure regulation and improved hemodynamic stability after SCI. In addition to immediate and sustained improved blood pressure levels, participants taking anti-hypotension drugs prior to the study significantly reduced or discontinued their medication. Participants also reported improved general well-being and a reduction in orthostatic hypotension, including reduced dizziness and increased energy. Detailed interim results from these studies are expected to be published later this year. Managing blood pressure instability is among the major unmet needs for which the FDA has awarded the Company one of its 10 Breakthrough Device Designations. This award is reserved for novel, cutting-edge therapies addressing unmet needs and provides potential regulatory and reimbursement benefits. To stay informed about ONWARD's research studies, technologies, and the availability of therapies in your area, please complete this webform. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries, and other movement disabilities. Building on over a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device designations from the FDA. The Company's ARC-EX® System is cleared for commercial sale in the US. The Company is also developing an investigational implantable system called ARC-IM, which can be paired with a brain-computer interface (BCI) to restore thought-driven movement. Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, please visit For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Notes and references: 1. Katzelnick CG et al. Blood Pressure Instability in Persons With SCI: Evidence From a 30-Day Home Monitoring Observation. Am J Hypertens. 2019 Sep 24;32(10):938-944 2. Carlozzi, N. E. et al. Impact of blood pressure dysregulation on health-related quality of life in persons with spinal cord injury: development of a conceptual model. Arch. Phys. Med. Rehabil. 94, 1721–1730 (2013) 3. Squair, J.W. et al. Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury. Nature 590, 308–314 (2021) Forward-Looking Statements Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Prenatal Pesticide Exposure Alters Children's Brain Development, Impairing Motor Skills
Exposure during pregnancy to chlorpyrifos, a widely used pesticide, causes lasting changes in children's brains and motor function impairments. LOS ANGELES, August 18, 2025--(BUSINESS WIRE)--A joint observational study by Children's Hospital Los Angeles (CHLA) and Columbia University has found that prenatal exposure to a common pesticide also used as an insecticide could impair children's brain development and motor function for years to come. In this long-term study of children between 6 and 14 years old, followed since birth, prenatal exposure to the pesticide chlorpyrifos (CPF) was associated with alterations in brain structure and impairments in motor function. This is the first study to show that prenatal exposure to a pesticide produces enduring and widespread molecular, cellular, and metabolic effects in the brain. The results were published in JAMA Neurology. "More CPF exposure led to more thickening of the cerebral cortex—the area of the brain that directs functions like thinking, memory and movement," says Bradley Peterson, MD, first author on the study and Chief of the Division of Child & Adolescent Psychiatry at Children's Hospital, where he also leads the Brain Imaging Lab. "We don't know the consequences of these brain effects, but we found that CPF exposure most impairs motor functioning." Fetal exposure to CPF affects neurological development Between January 1998 and July 2005, the team conducted behavioral assessments and MRI scans of the brains of 270 youths in upper Manhattan whose mothers had been exposed to CPF during pregnancy when their apartments were fumigated. The researchers from CHLA and the Columbia University Mailman School of Public Health also accessed behavioral exposure information from umbilical cord samples from each child at delivery as well as samples of their mothers' blood collected the day after birth. The MRI scans found: Thickening of the brain cortex Alterations in white matter, which could affect brain function Changes in the internal capsule, the structure that governs communication between the cortex and subcortical areas, affect motor and sensory pathways Fewer neurons in white matter could signal impaired development Abnormalities in brain pathways that support motor control Impaired nerve insulation (myelination), which can affect function Reduced blood flow, indicating less energy use, throughout the brain "Current widespread exposures, at levels comparable to those experienced in this sample, continue to place farm workers, pregnant women, and unborn children in harm's way. It is vitally important that we continue to monitor the levels of exposure in potentially vulnerable populations, especially in pregnant women in agricultural communities, as their infants continue to be at risk," said Virginia Rauh, ScD, senior author on the study and the Jane and Alan Batkin Professor of Population and Family Health at Columbia Mailman School. The data strongly suggest that one of the fundamental problems of CPF exposure is altered differentiation of neuronal tissue, says Dr. Peterson. "That happens early in pregnancy, when neurons develop in the cortex and differentiate into cortical gray matter—densely packed nerve cells which process information—and underlying white matter—which is mostly nerve fibers that connect neurons," he says. "All these abnormalities can contribute to poor motor function in these kids. The contributing mechanisms seem to be the inflammation and oxidative stress that CPF and other pesticides produce." The researchers also found a dramatic and global reduction in brain blood flow. "To me, this is the most profound finding because it's so powerful and very rare to see something like this," says Dr. Peterson. "Blood flow is an important indicator of underlying metabolism—the energy used by brain tissue. In my opinion, it's maybe the most important finding of the paper, because it says that globally there's a problem with brain metabolism in direct proportion to how much CPF exposure they had." While this current paper reports results on children up to age 14, the researchers have now collected MRI scans of adolescents up to age 19 and are analyzing the data in preparation for the next release of results from this ongoing study. CPF is in the food chain CPF is an organophosphate pesticide—in the same chemical family as nerve gas–that disrupts nerve signaling. In pregnancy, it can cross the placenta to the fetus, easily traversing the fetal blood-brain barrier. Prior studies by other groups have linked maternal CPF exposure to lower birth weight, smaller head size, abnormal newborn reflexes, and neurodevelopmental issues in toddlers—including autism, inattention, and lower intelligence. CPF was banned from home use in the U.S. in 2001, but it is still used as an agricultural pesticide. A 2020 ban on food crops was reversed in 2023. The EPA wants to continue to allow CPF residues in certain food crops, including apples, strawberries, asparagus, tart cherries, citrus, and peaches. "It's in our food supply," cautions Dr. Peterson. "And other chemicals used in the home act in similar ways and almost certainly increase inflammation and oxidative stress. This is why it is important to do these studies about the chemicals in our environment to protect children's health." Editor's note: An embargoed copy of the study can be obtained from JAMA Neurology (mediarelations@ or CHLA can provide a copy. About Children's Hospital Los Angeles Children's Hospital Los Angeles is at the forefront of pediatric medicine and is the largest provider of hospital care for children in California. Since its founding in 1901, CHLA has delivered a level of pediatric care that is among the best in the world. Ranked one of the top 10 children's hospitals in the nation by U.S. News & World Report, Children's Hospital Los Angeles provides comprehensive and compassionate care to one of the largest and most diverse pediatric patient populations in the country. The hospital is the top-ranked children's hospital in California and the Pacific U.S. region for 2024-25. A leader in pediatric research, CHLA is among the top 10 children's hospitals for research funding from the National Institutes of Health. The Saban Research Institute of Children's Hospital Los Angeles supports the full continuum of research, translating scientific discoveries into life-changing treatments for patients around the globe. As a pediatric academic medical center, CHLA is also home to one of the largest graduate education programs for pediatricians in the United States. The hospital's commitment to building stronger, healthier communities is evident in CHLA's efforts to enhance health education and literacy, introduce more people to careers in health care, and fight food insecurity. To learn more, follow CHLA on Facebook, Instagram, LinkedIn, YouTube, and X, and visit View source version on Contacts CHLA Contact: Lorenzo Benet e: lbenet@ Sign in to access your portfolio
Associated Press
4 hours ago
- Associated Press
Centerline Biomedical Appoints Jim Dillon President and Chief Executive Officer
CLEVELAND--(BUSINESS WIRE)--Aug 18, 2025-- Centerline Biomedical, Inc. ('Centerline'), an innovative leader in cardiovascular navigation and visualization systems, announced the appointment of Jim Dillon as President and Chief Executive Officer (CEO) and a member of its board of directors. He will assume his responsibilities on August 18, 2025. Mr. Dillon succeeds Gulam Khan, who has served as CEO since October 2022. Mr. Khan led Centerline Biomedical through a period of portfolio development. During his tenure, Centerline Biomedical developed, received 510(k) clearance, and commercialized its second-generation devices and appreciable software advances. We appreciate Gulam's significant contributions. 'It is an honor to join Centerline at such a pivotal stage. The IOPS platform is poised for scaled growth and I am grateful to have the opportunity to lead the company as it continues to innovate such remarkable technology for patients and care givers,' said Mr. Dillon. 'With decades of med tech industry leadership, Jim brings deep cardiovascular sector experience leading portfolio innovation, operational alignment, and strategic financing for med tech companies,' said Todd Schwarzinger, Centerline's Chairman. 'Jim has a strong track record of driving commercial growth through category creation and market penetration and we are excited to have him leading Centerline.' Mr. Dillon has previously served as President and CEO for cardiovascular innovation companies; BiVACOR, BioVentrix, Reprieve Cardiovascular and Renal Guard Solutions. To learn more about the IOPS platform, visit About Centerline Biomedical Founded in 2015, Centerline Biomedical, Inc. is headquartered in Cleveland, Ohio. The company's commercially available platform, IOPS® (Intra-Operative Positioning System), enables improved visualization and device navigation, while protecting patient and healthcare provider exposure from the harmful effects of fluoroscopic X-ray radiation during standard interventions. The company is a Cleveland Clinic Innovations spin-off investing in commercialization and development of technology to improve image guidance and reduce the need for fluoroscopic x-ray during transcatheter procedures. IOPS is indicated for use in the peripheral, aortic and aortic side branch vasculature. The IOPS platform consists of a mobile cart powered by proprietary visualization software and intelligent, sensorized IOPS catheters and guidewires. Visit for more information. View source version on CONTACT: For inquiries, please contact: Patty Burns, SVP Marketing Centerline Biomedical, Inc. Email:[email protected] KEYWORD: UNITED STATES NORTH AMERICA OHIO INDUSTRY KEYWORD: CARDIOLOGY SOFTWARE RADIOLOGY HEALTH MEDICAL DEVICES HOSPITALS HEALTH TECHNOLOGY TECHNOLOGY SOURCE: Centerline Biomedical, Inc. Copyright Business Wire 2025. PUB: 08/18/2025 11:00 AM/DISC: 08/18/2025 11:00 AM
